Pınar Kubilay Tolunay

7PUBLICATIONS
49CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 26, 2026
Upfront Versus Deferred CDK4/6 Inhibitor Use in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study.

|May 27, 2026
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis.

|Jan 09, 2026
Chemotherapy tolerance and continuity are prognostic for overall survival in patients with localized and advanced biliary tract cancer.

Erman Akkuş, Pınar Kubilay Tolunay, Elif Berna Köksoy

|Jul 02, 2025
Comparison of AI chatbot predicted and realworld survival outcomes in hepatocellular carcinoma.

Engin Eren Kavak, Efe Cem Erdat, Zeynep Altundağ Derin

|Feb 26, 2025
A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy.

İrem Öner, Hicran Anık, Bediz Kurt İnci

|Dec 27, 2024
Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors.

Pınar Kubilay Tolunay, Bediz Kurt İnci, Şura Usta

Pageof 2

Frequent Collaborators

3 joint publications

Öztürk Ateş

2 joint publications

Hakan Akbulut

2 joint publications

Hatime Arzu Yaşar

1 joint publications

Cengiz Karaçin